Brief: Kiniksa Pharmaceuticals Reports Q3 Results

Kiniksa Pharmaceuticals International

01/11/2022 12:39

Nov 1 (Reuters) - Kiniksa Pharmaceuticals Ltd  KNSA.O :
    * KINIKSA PHARMACEUTICALS REPORTS THIRD QUARTER 2022
FINANCIAL
RESULTS AND PROVIDES CORPORATE UPDATE
    * ARCALYST (RILONACEPT) Q3 2022 NET REVENUE OF $33.4 MILLION
    * KPL-404 PHASE 2 DATA IN RHEUMATOID ARTHRITIS EXPECTED IN
1H 2024
    * CASH RESERVES OF $200.7 MILLION EXPECTED TO FUND
OPERATIONS INTO
AT LEAST 2025
    * QTRLY EPS $3.18
    * Q3 EARNINGS PER SHARE VIEW $0.78 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX8SBGQV 
Further company coverage:  KNSA.O 
 ((Reuters.Briefs@thomsonreuters.com;))